Shares of pharmaceutical company Merck (MRK) show a strong growth in premarket trading. The reason for rise in price of securities, as reported by CNNMoney, is the fact that on Tuesday night, the company reported that the US Food and Drug Administration (US Food and Drug Administration) is considering an accelerated approval of the drug for the treatment of lung cancer, Keytruda.
MRK shares rose to $ 61.65 (+ 2.89%).
The post Merck shars (MRK) rose by 3% premarket on the back of positive information about Keytruda drug appeared first on forex-analytics.press.